Literature DB >> 22717417

Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study.

Gustavo Lamego de Barros Costa1, Rosana Morais Lamego, Enrico A Colosimo, Reginaldo Aparecido Valacio, Maria da Consolação Vieira Moreira.   

Abstract

BACKGROUND: The efficacy and risks of oral anticoagulation are largely associated with maintaining the quality of anticoagulation control. Nevertheless, few studies have addressed which factors, if any, are associated with this control.
OBJECTIVE: This study aimed to identify predictors of high-quality oral anticoagulation.
METHODS: A prospective observational study enrolled all adult patients on intended long-term oral anticoagulation attending a public anticoagulation clinic. Patients with high-quality anticoagulation, defined as percentage of time in therapeutic international normalized ratio (INR) range (TTR) ≥66%, were compared with those with poor anticoagulation control (TTR <66%). Measures included cognitive, psychological, and relevant behavioral factors, in addition to traditionally implicated ones, such as age, comorbidity, and concurrent medications.
RESULTS: Participation was requested from all 233 patients followed up at the anticoagulation clinic. Eighty-six did not meet the inclusion criteria (49 due to intended anticoagulation duration <90 days, 37 due to the need for a caregiver responsible for medications). A total of 147 patients were enrolled, of whom 13 (8.8%) were lost to follow-up. Therefore, data were analyzed from 134 patients (mean [SD] age, 55 [14.2] years [range, 19-87 years]), who were followed up for a mean (SD) duration of 272 (87) days. The total mean TTR was 64.7%, which is comparable to values achieved in clinical trials. The good-control group had 61 patients (45.5%) (mean TTR, 77.7% [8.5%]) and the poor-control group had 73 patients (54.5%) (mean TTR, 50.4 [11.7%]). On multivariate logistic regression analysis, high-quality anticoagulation was independently associated with regular vitamin K intake, expressed by its variability in daily dosage (odds ratio [OR] = 0.79; 95% CI, 0.64-0.98); male sex (OR = 2.41; 95% CI, 1.06-5.49); duration of anticoagulation treatment >2 months (OR = 3.23; 95% CI, 1.25-8.36); presence of family support (OR = 3.32; 95% CI, 1.16-9.48); functional and cognitive ability to take medications as prescribed, defined as good medication management capacity (MMC; as assed using the Drug Regimen Unassisted Grading Scale) (OR = 4.18; 95% CI, 1.63-10.68); and no regular use of alcohol (OR = 8.59; 95% CI, 1.45-51.09).
CONCLUSIONS: The data suggest that independent predictors of high-quality oral anticoagulation included regular vitamin K intake, male sex, duration of anticoagulation treatment >2 months, presence of family support, good MMC, and no regular alcohol use. These findings may help clinicians to decide whether to start anticoagulation in intermediate-risk patients, to identify patients who will require closer attention on their anticoagulation management, and to direct their efforts to improve the quality of oral anticoagulation.
Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22717417     DOI: 10.1016/j.clinthera.2012.06.002

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  8 in total

1.  Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin.

Authors:  Marcus Fernando S Praxedes; Maria Auxiliadora P Martins; Aline O M Mourão; Karina B Gomes; Edna A Reis; Renan P Souza; Emílio Itamar F Campos; Daniel D Ribeiro; Manoel Otávio C Rocha
Journal:  Eur J Clin Pharmacol       Date:  2019-11-12       Impact factor: 2.953

2.  Pharmacists' influence on adverse reactions to warfarin: a randomised controlled trial in elderly rural patients.

Authors:  Slaven Falamić; Marko Lucijanić; Maja Ortner-Hadžiabdić; Srećko Marušić; Vesna Bačić-Vrca
Journal:  Int J Clin Pharm       Date:  2019-09-07

3.  Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional study.

Authors:  Agnes Rouaud; Olivier Hanon; Anne-Sophie Boureau; Guillaume Chapelet; Guillaume Gilles Chapelet; Laure de Decker
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

Review 4.  Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences.

Authors:  Jeff R Schein; C Michael White; Winnie W Nelson; Jeffrey Kluger; Elizabeth S Mearns; Craig I Coleman
Journal:  Thromb J       Date:  2016-06-13

5.  Educational Level, Anticoagulation Quality, and Clinical Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study.

Authors:  Eveline Hofmann; Nicolas Faller; Andreas Limacher; Marie Méan; Tobias Tritschler; Nicolas Rodondi; Drahomir Aujesky
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

6.  Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge.

Authors:  Samantha Wasniewski; Luciano Consuegra-Sánchez; Pablo Conesa-Zamora; Luis García de Guadiana-Romualdo; Pablo Ramos-Ruiz; Marta Merelo-Nicolás; F Guillermo Clavel-Ruipérez; Begoña Alburquerque-González; Federico Soria-Arcos; Juan A Castillo-Moreno
Journal:  Biomed Res Int       Date:  2018-10-17       Impact factor: 3.411

7.  Quality of anticoagulation control among patients with atrial fibrillation: An experience of a tertiary care center in Saudi Arabia.

Authors:  Sarah M Alyousif; Ahmed A Alsaileek
Journal:  J Saudi Heart Assoc       Date:  2016-02-11

8.  Management strategies following slightly out-of-range INRs: watchful waiting vs dose changes.

Authors:  Hallie B Remer; Xiaokui Gu; Brian Haymart; Geoffrey D Barnes; Mona A Ali; Eva Kline-Rogers; Tina Alexandris-Souphis; Jay H Kozlowski; James B Froehlich; Vinay Shah; Gregory D Krol; Scott Kaatz
Journal:  Blood Adv       Date:  2022-05-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.